Mid Glamorgan, United Kingdom

Magitha Maheshwar

This inventor holds 1 USPTO granted patent. Top assignee: Medical Research Council. Active years: 2001.


% Patents Active = 100.0

Average Co-Inventor Count = 12.0

ph-index = 1


Company Filing History:


Years Active: 2001

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Magitha Maheshwar: Innovator in Genetic Research

Introduction

Magitha Maheshwar is a prominent inventor based in Mid Glamorgan, GB. He has made significant contributions to the field of genetic research, particularly in relation to tuberous sclerosis. His work has implications for both diagnosis and treatment of this genetic disorder.

Latest Patents

Magitha holds a patent titled "Tuberous sclerosis 2 gene and uses thereof." This patent addresses tuberous sclerosis (TSC), an autosomal dominant disorder characterized by the development of growths in various tissues and organs. The gene TSC2, identified on chromosome 16, is mutated in TSC and may function as a tumor suppressor. The screening of actual or suspected TSC patients for normal or mutated TSC2 can be utilized for diagnostic purposes. Furthermore, the TSC2 protein, known as tuberin, may be employed to treat or prevent unrestrained cell division and tumor development in patients with or without TSC.

Career Highlights

Magitha is affiliated with the Medical Research Council, where he conducts his research. His work has been instrumental in advancing the understanding of tuberous sclerosis and its genetic underpinnings.

Collaborations

He has collaborated with notable colleagues, including Julian R Sampson and Mark David Nellist, to further his research endeavors.

Conclusion

Magitha Maheshwar's innovative work in genetic research, particularly concerning tuberous sclerosis, highlights the importance of understanding genetic disorders for better diagnostic and therapeutic strategies. His contributions continue to impact the field significantly.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…